MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.

2021-01-07

Practicing and Managing Complex Patients in the COVID-19 Era

A discussion with Dr. Andrew Vellathottam and Don Watts, President, Khure Health

The COVID-19 pandemic has made this year an incredibly challenging time for patients and the healthcare system – especially patients with rare and complex conditions. Don Watts, President of Khure Health sat down with Dr. Andrew Vellathottam, a family physician and FHO group lead in Scarborough, Ontario to learn how primary care physicians are adapting to practicing during COVID-19.

Don Watts: Iappreciate you taking the time to talk today Dr. Vellathottam.  We’re all so grateful to everyone in healthcare for all that is being done during these difficult times, and certainly to all primary care providers, like yourself, who have also had to make significant changes to practice management and patient care to ensure everyone’s safety  Let me start by asking you about some of the key challenges you have faced managing patient care since the onset of COVID-19?

Dr. Vellathottam: At the beginning of the pandemic, we were already a little ahead of the game. I had signed up and been using OTN to get virtual care going well before lockdown and had been doing phone appointments with patients before COVID-19 hit. For me it was about being more accessible to patients – bridging the gap of location and geography by enabling them to connect virtually. In the spring, as the first wave peaked, we were very comfortable with telephone/virtual based appointments. In those early days, in-person visits were definitely down but we were still able to keep up with paediatric vaccines as well as urgent visits that needed a quick assessment for treatment or referral. There were definitely some virtual visits that could have benefitted from being in person which did create some inefficiencies in terms of the practice – with something that would have taken one visit ended up having to take two.

DW: How are you managing risk of infection and transmission in your practice?

Dr. V: One of the ways that we managed risk early on was just to be mindful of what warranted a physical, in person visit. Especially now, as we enter this second wave, we are pulling back on visits. For example, we are aren’t doing annual health exams – the benefit of that kind of visit just doesn’t balance with the risk. We have also implemented strict protocols in accordance with public health guidance: call first, reducing touch points in the clinic, enforcing distancing as well as mandatory mask wearing for everyone in the clinic.

DW: How are you balancing the current risks with the needs of your complex or chronic care patients? What percentage of your practice do they represent?

Dr. V: Chronic and complex patients represent about 50% of my practice. We opened up to in-person treatment of our chronic care patients (diabetic, hyper-tension, heart disease, etc.) in June. It really is a balancing act to ensure they have the appropriate care while minimizing risk of exposure to the virus. Many of these patients have co-morbidities that would create serious complications if they were to contract COVID-19.

Our approach has been to combine what would have been multiple visits or touch points pre-COVID-19, to get as much done as possible in one visit: blood work, blood pressure, additional lab work, etc. We believe that if we can get them in once, reduce their touch points in the office and get everything done, we are giving these patients the best possible care to manage their conditions while minimizing risk to exposure.

DW: What role does technology play in your practice, especially when it comes to managing complex conditions and the potential impact of COVID-19 on their health?

Dr. V: We are actively reviewing our EMR and proactively calling patients who need to be managing their complex care. I am also a big fan of assistive technology to help me in proactively identifying high-risk patients and diagnosing some of the more complex and rarer conditions. There is a wealth of data in the EMR and technologies like artificial intelligence are very exciting because it can take all that information for every patient in the practice –  from reports, medication lists, lab work, patient history, and physician notes – and analyse it very quickly. I’m now using the Khure Health AI-enabled clinical dashboard that can take that data and match it against up-to-date diagnostic criteria to surface those patients who may be at greater risk of rare diseases, let me screen patients I just can’t put my finger on, and alert us to those patients who could be at very serious risk if they contract COVID-19. These tools are extremely helpful for physicians to be able to make accurate and timely diagnoses and limit disease progression.

DW: I’m grateful for your time today Dr. Vellathottam.  Last question!  What are the biggest lessons you have learned as you have adapted your practice this year?

Dr. V: It would be naïve to think that COVID-19 is the only virus we will have to deal with and it has really made us and community offices reflect on infection protocols and adapt to ensure we can manage patients, in particular complex and chronic care, high risk patients in the backdrop of a highly contagious, life-threatening viral infection. You can create an efficient practice with reduced exposure: taking care of things all at once, reducing your patients’ touch points, virtual and telephone appointments for simple things – these ongoing practices will make patient management and care much better from an infectious disease management perspective. I believe that these preventative infection controls will carry forward.

Khure Health’s AI-powered Clinical Intelligence Platform enables physicians to quickly understand patients at risk of a complex or rare disease and identify the right care pathways. For more information visit www.khurehealth.ca

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.

Audience and Appropriate Topics

The  Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement